Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 5Recruiting 2Active not recruiting 2Unknown 1Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Leukemia 1Adenocarcinoma 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Valacyclovir × Clear all
NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

M.D. Anderson Cancer Center

Phase 2 Recruiting
60 enrolled
Other hematologic neoplasm

Leukemia

NCT07332000 2026-03-20

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Candel Therapeutics, Inc.

Phase 2 Recruiting
45 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡